- Express Scripts to Buy Medco Health For $29B, Shares Up
July 21 2011 11:07 AM
Express Scripts, Inc. (NASDAQ:ESRX) said it agreed to buy Medco Health Solutions, Inc. (NYSE:MHS) for $29.1 billion cash and stock deal that would see Express Scripts becoming the largest pharmacy-benefits manager in the U.S.
- Max Shacknai Dies; Medicis CEO's Mansion Sees Two Deaths in a Week
July 18 2011 11:11 AM
Max Shacknai, the 6-year-old-son of Medecis Pharmaceuticals CEO Jonah Shacknai died after sustaining injuries from last week's accident.
- Medicis Corp. CEO Girlfriend Found Dead, Shares Drop
July 15 2011 10:12 AM
Rebecca Nalepa, 32, girlfriend of Medicis Pharmaceutical Corp., a pharmaceutical company based in Scottsdale, Ariz., founder and chief executive Jonah Shacknai, was found dead at his California home, one of many in a wealthy neighborhood, Wednesday in what officials are calling suspicious circumstances.
- McDonald's Not On Board With Healthier Options Initiative : We listen to our customers...
July 14 2011 10:30 AM
McDonald's has undergone major changes since it has been pressured over the years for its super unhealthier but cheap options. Its Happy Meal already meets guidelines for the NRA's initiative as it is only 390 calories (4 piece chicken McNuggets, Apple Dippers with low-fat carmel, and low-fat milk.) Here are some of McDonald's healthier options for children and adults.
- Pfizer Considering Sale of Animal Health, Baby Food Units
July 07 2011 4:26 PM
Pharmaceutical giant Pfizer (PFE) is considering selling its animal health and baby food units in hopes of appeasing shareholders' demands.
- Medicare to pay for Avastin regardless of FDA
July 03 2011 12:50 PM
The Centers of Medicare and Medicaid said that Medicare will continue to pay for ?Avastin? when it is prescribed to treat metastatic breast cancer, regardless of what the FDA would decide.
- FDA: Silicone-gel Breast Implants Relatively Safe
June 23 2011 1:49 PM
FDA follow-up study on silicone-gel breast implants returned to market for patients in 2006 concludes they are safe, but won't last forever.
- New York Post website blocks Safari access via iPad
June 19 2011 6:16 AM
New York Post has set up a new paywall blocking iPad access via Safari, a web browser, to its website directing the users to download the publication's app through the App Store.
- Major drug companies cut vaccine prices in developing countries
June 06 2011 8:45 AM
A group of major western pharmaceutical companies announced that they will significantly reduce the prices they charge for vaccines in the developing world.
- Medco Health Lost FEP Contract, a Signal for More Aggressive Pricing?
May 31 2011 8:10 AM
FBR Capital Markets lowered its price target on shares of Medco Health Solutions Inc. (NYSE: MHS) by $4 to $71, while maintaining its outperform rating. The brokerage said it maintained its rating despite the recent announcement of Medco losing $3 billion of annual revenue from Federal Employees Program (FEP) contract going to competitor CVS Caremark Corp. (NYSE: CVS).
- Which stocks should be sold now?
May 27 2011 4:11 AM
Wall Street investment guru and editor of GameChangers Hilary Kramer has put together a list of 12 stocks which she advised investors to sell immediately. While the names that appeared on the list are big ticket stocks, Kramer justifies her position, saying that investors usually make the mistake of holding on to what used to be hot previously. She says, for example, retail stocks were 'yesterday’s market leaders.'
- Cephalon Investor Meeting Takeaways on Acquisiton by Teva: Analyst
May 19 2011 10:32 AM
RBC Capital Markets hosted an investor meeting with Cephalon Inc.'s (NASDAQ: CEPH) chief financial officer Wilco Groenhuysen and chief marketing officer Lesley Russell. The brokerage listed out key takeaways regarding the proposed acquisition of Cephalon by Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA).
- Bill Gates upbeat on vaccines mission at WHO (PHOTOS)
May 17 2011 10:03 AM
William Henry Bill Gates III, co-chair of the Bill & Melinda Gates Foundation, laid out his vision for the impact that broadening access to vaccines can have on the world.
- Oppenheimer's Top Stocks for May (V, QCOM, BRCM, C, CHKP, CMCSA, MRO, CI)
May 16 2011 8:33 AM
Following are the Oppenheimer's top equity ideas for May. The stocks are based on their view of the company's fundamentals in the context of current market conditions.
- Xoma Could Initiate Pivotal Behcet’s Trial by Year-End 2011: Analyst
May 10 2011 9:46 AM
RBC Capital Markets said Xoma Ltd. (NASDAQ: XOMA) continues to make steady albeit measured progress toward initiating a pivotal trial in Behcet’s disease, which could begin by year-end 2011, pending regulatory feedback.
- Week Ahead in Life Sciences
May 09 2011 7:31 AM
Wedbush Securities said that among the companies it covered in Life Sciences this week Chelsea Therapeutics International Ltd. (NASDAQ: CHTP) and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) are reporting earnings.
- Cash Runway Expected for Xoma Through Start of Phase 3 Behcet's Uveitis Study: Analyst
May 09 2011 7:30 AM
Wedbush Securities expects cash runway for XOMA Ltd. (NASDAQ: XOMA) through start of phase 3 Behcet’s Uveitis study by year-end 2011. The brokerage maintained its outperform rating on shares of Xoma with a fair value estimate of $16.
- Synta Pharma Phase 2 Data to Help Assess Potential For Ganetespib: Analyst
May 06 2011 10:12 AM
RBC Capital Markets expects that Synta Pharmaceuticals Corp.'s (NASDAQ: SNTA) upcoming phase 2 data for ganetespib or STA-9090 in combination with docetaxel in non-small cell lung cancer could help investors more accurately assess the potential for ganetespid.
- Vertex Pharma Hepatitis C Drug Incivek Likely to be Approved by May 23: Analyst
May 04 2011 9:21 AM
RBC Capital Markets expects Vertex Pharmaceuticals Inc.'s (NASDAQ: VRTX) Incivek (telaprevir) to treat hepatitis C is likely to be approved on or around May 23.
- FDA OKs new treatment for Type 2 diabetes
May 04 2011 4:12 AM
The U.S. Food and Drug Administration (FDA) approved Tradjenta (linagliptin) tablets, used with diet and exercise, to improve blood glucose control in adults with Type 2 diabetes. Tradjenta is marketed by Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Conn., and Indianapolis-based Eli Lilly Co.